A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma

Devalingam Mahalingam, Christos Fountzilas, Jennifer Moseley, Nicole Noronha, Hue Tran, Romit Chakrabarty, Giovanni Selvaggi, Matthew Coffey, Brad Thompson, John Sarantopoulos

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

REOLYSIN® (pelareorep) is an investigational new drug, consisting of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary formulation. Several preclinical and clinical trials with REOLYSIN® on a wide range of cancer indications have demonstrated antineoplastic activity on cells with activated RAS-signaling pathway. Furthermore, long-term survival benefits were evident in post-treatment patients indicating a potential antitumor immune response triggered by REOLYSIN®. Numerous mono and/or combination therapy studies with the agent showed a consistent safety profile. The current study is a phase II, single-arm, open label trial of REOLYSIN® in combination with carboplatin and paclitaxel for patients with advanced melanoma. Results from the 14 patients enrolled in the study exhibited no grade 4 adverse events or deaths but manageable grade-3 toxicities commonly attributed to REOLYSIN®, including pyrexia, chills, myalgia, pain, fatigue, and nausea. The number of treatment cycles ranged from 2 to 20 with a median of 6 cycles. The study met its treatment and efficacy goal for the first stage with three partial responses (ORR was 21%). No complete responses were noted. The median PFS and OS were 5.2 and 10.9 months, respectively. The 1-year OS was 43% with a disease control rate of 85%. In conclusion, REOLYSIN® combined with carboplatin and paclitaxel is a safe and potentially efficacious therapy for patients with advanced malignant melanoma. Additional combination studies using REOLYSIN® with chemo/immunotherapy drugs may support more favorable outcomes for patients in this indication.

Original languageEnglish (US)
Pages (from-to)697-703
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume79
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Carboplatin
Paclitaxel
Melanoma
Patient treatment
Investigational Drugs
Disease control
Antineoplastic Agents
Toxicity
Labels
Fatigue of materials
Mammalian orthoreovirus 3
Chills
Pharmaceutical Preparations
Myalgia
Therapeutics
Immunotherapy
Nausea
Fatigue
Fever
Clinical Trials

Keywords

  • Melanoma
  • Oncolytic virus
  • Pelareorep
  • REOLYSIN
  • Reovirus

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. / Mahalingam, Devalingam; Fountzilas, Christos; Moseley, Jennifer; Noronha, Nicole; Tran, Hue; Chakrabarty, Romit; Selvaggi, Giovanni; Coffey, Matthew; Thompson, Brad; Sarantopoulos, John.

In: Cancer Chemotherapy and Pharmacology, Vol. 79, No. 4, 01.04.2017, p. 697-703.

Research output: Contribution to journalArticle

Mahalingam, D, Fountzilas, C, Moseley, J, Noronha, N, Tran, H, Chakrabarty, R, Selvaggi, G, Coffey, M, Thompson, B & Sarantopoulos, J 2017, 'A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma', Cancer Chemotherapy and Pharmacology, vol. 79, no. 4, pp. 697-703. https://doi.org/10.1007/s00280-017-3260-6
Mahalingam, Devalingam ; Fountzilas, Christos ; Moseley, Jennifer ; Noronha, Nicole ; Tran, Hue ; Chakrabarty, Romit ; Selvaggi, Giovanni ; Coffey, Matthew ; Thompson, Brad ; Sarantopoulos, John. / A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. In: Cancer Chemotherapy and Pharmacology. 2017 ; Vol. 79, No. 4. pp. 697-703.
@article{e7479b666fc8423dba5789eb7298b849,
title = "A phase II study of REOLYSIN{\circledR} (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma",
abstract = "REOLYSIN{\circledR} (pelareorep) is an investigational new drug, consisting of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary formulation. Several preclinical and clinical trials with REOLYSIN{\circledR} on a wide range of cancer indications have demonstrated antineoplastic activity on cells with activated RAS-signaling pathway. Furthermore, long-term survival benefits were evident in post-treatment patients indicating a potential antitumor immune response triggered by REOLYSIN{\circledR}. Numerous mono and/or combination therapy studies with the agent showed a consistent safety profile. The current study is a phase II, single-arm, open label trial of REOLYSIN{\circledR} in combination with carboplatin and paclitaxel for patients with advanced melanoma. Results from the 14 patients enrolled in the study exhibited no grade 4 adverse events or deaths but manageable grade-3 toxicities commonly attributed to REOLYSIN{\circledR}, including pyrexia, chills, myalgia, pain, fatigue, and nausea. The number of treatment cycles ranged from 2 to 20 with a median of 6 cycles. The study met its treatment and efficacy goal for the first stage with three partial responses (ORR was 21{\%}). No complete responses were noted. The median PFS and OS were 5.2 and 10.9 months, respectively. The 1-year OS was 43{\%} with a disease control rate of 85{\%}. In conclusion, REOLYSIN{\circledR} combined with carboplatin and paclitaxel is a safe and potentially efficacious therapy for patients with advanced malignant melanoma. Additional combination studies using REOLYSIN{\circledR} with chemo/immunotherapy drugs may support more favorable outcomes for patients in this indication.",
keywords = "Melanoma, Oncolytic virus, Pelareorep, REOLYSIN, Reovirus",
author = "Devalingam Mahalingam and Christos Fountzilas and Jennifer Moseley and Nicole Noronha and Hue Tran and Romit Chakrabarty and Giovanni Selvaggi and Matthew Coffey and Brad Thompson and John Sarantopoulos",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s00280-017-3260-6",
language = "English (US)",
volume = "79",
pages = "697--703",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma

AU - Mahalingam, Devalingam

AU - Fountzilas, Christos

AU - Moseley, Jennifer

AU - Noronha, Nicole

AU - Tran, Hue

AU - Chakrabarty, Romit

AU - Selvaggi, Giovanni

AU - Coffey, Matthew

AU - Thompson, Brad

AU - Sarantopoulos, John

PY - 2017/4/1

Y1 - 2017/4/1

N2 - REOLYSIN® (pelareorep) is an investigational new drug, consisting of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary formulation. Several preclinical and clinical trials with REOLYSIN® on a wide range of cancer indications have demonstrated antineoplastic activity on cells with activated RAS-signaling pathway. Furthermore, long-term survival benefits were evident in post-treatment patients indicating a potential antitumor immune response triggered by REOLYSIN®. Numerous mono and/or combination therapy studies with the agent showed a consistent safety profile. The current study is a phase II, single-arm, open label trial of REOLYSIN® in combination with carboplatin and paclitaxel for patients with advanced melanoma. Results from the 14 patients enrolled in the study exhibited no grade 4 adverse events or deaths but manageable grade-3 toxicities commonly attributed to REOLYSIN®, including pyrexia, chills, myalgia, pain, fatigue, and nausea. The number of treatment cycles ranged from 2 to 20 with a median of 6 cycles. The study met its treatment and efficacy goal for the first stage with three partial responses (ORR was 21%). No complete responses were noted. The median PFS and OS were 5.2 and 10.9 months, respectively. The 1-year OS was 43% with a disease control rate of 85%. In conclusion, REOLYSIN® combined with carboplatin and paclitaxel is a safe and potentially efficacious therapy for patients with advanced malignant melanoma. Additional combination studies using REOLYSIN® with chemo/immunotherapy drugs may support more favorable outcomes for patients in this indication.

AB - REOLYSIN® (pelareorep) is an investigational new drug, consisting of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary formulation. Several preclinical and clinical trials with REOLYSIN® on a wide range of cancer indications have demonstrated antineoplastic activity on cells with activated RAS-signaling pathway. Furthermore, long-term survival benefits were evident in post-treatment patients indicating a potential antitumor immune response triggered by REOLYSIN®. Numerous mono and/or combination therapy studies with the agent showed a consistent safety profile. The current study is a phase II, single-arm, open label trial of REOLYSIN® in combination with carboplatin and paclitaxel for patients with advanced melanoma. Results from the 14 patients enrolled in the study exhibited no grade 4 adverse events or deaths but manageable grade-3 toxicities commonly attributed to REOLYSIN®, including pyrexia, chills, myalgia, pain, fatigue, and nausea. The number of treatment cycles ranged from 2 to 20 with a median of 6 cycles. The study met its treatment and efficacy goal for the first stage with three partial responses (ORR was 21%). No complete responses were noted. The median PFS and OS were 5.2 and 10.9 months, respectively. The 1-year OS was 43% with a disease control rate of 85%. In conclusion, REOLYSIN® combined with carboplatin and paclitaxel is a safe and potentially efficacious therapy for patients with advanced malignant melanoma. Additional combination studies using REOLYSIN® with chemo/immunotherapy drugs may support more favorable outcomes for patients in this indication.

KW - Melanoma

KW - Oncolytic virus

KW - Pelareorep

KW - REOLYSIN

KW - Reovirus

UR - http://www.scopus.com/inward/record.url?scp=85015071483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015071483&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3260-6

DO - 10.1007/s00280-017-3260-6

M3 - Article

C2 - 28289863

AN - SCOPUS:85015071483

VL - 79

SP - 697

EP - 703

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -